HOME   |    PDF   |   


Title

VIP syndrome in oncology: prevalence, forms and ethical implications - A review

 

Authors

Dinesh Mohan 1, Manmohan Manmohan  2, Sangram Keshari Patro 3, Pooja Khandelwal 4, Yogesh Prakash Garud 5, Antaryami Sahoo 6,* & Abhinn Miglani 7

 

Affiliation

1Department of Surgical Oncology, IMS & SUM Medical College, SOA University, Bhubaneswar, Odisha, India; 2Department of Pathology, Pt. Bhagwat Dayal Sharma University of Health Sciences (UHS), Rohtak, Haryana, India; 3Department of Surgical Oncology, UTKAL Hospital, Bhubaneswar, Odisha, India; 4Department of Surgical Oncology, All India Institute of Medical Sciences (AIIMS), Sijua, Patrapada, Bhubaneswar, Odisha, India; 5Department of Surgical Oncology, Garud Hospital, Maharashtra, India; 6Department of Radiation Oncology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India; 7Department of Oral and Maxillofacial Surgery, Institute of Dental Sciences, SOA University, Bhubaneswar, Odisha, India; *Corresponding author

 

Email

Dinesh Mohan - E-mail: dineshmohan1009@gmail.com
Manmohan Manmohan - E-mail: manmohanyadav418@gmail.com
Sangram Keshari Patro – E-mail: jitun.04hell@gmail.com
Pooja Khandelwal - E-mail: pooja.khandelwal77@gmail.com
Yogesh Prakash Garud - E-mail: garudyogesh35@gmail.com
Antaryami Sahoo - E-mail: drantaryamisahoo2020@gmail.com
Abhinn Miglani - E-mail: abumiglani@gmail.com
 

Article Type

Review

 

Date

Received October 1, 2026; Revised October 31, 2026; Accepted October 31, 2026, Published October 31, 2026

 

Abstract

VIP syndrome refers to the preferential treatment of influential patients, posing ethical and clinical challenges in oncology where equitable resource allocation is essential. Therefore, it is of interest to examine the prevalence, manifestations and ethical implications of VIP syndrome in cancer care by synthesizing evidence from recent literature across diagnostic, therapeutic and administrative domains. Preferential treatment was reported most frequently in academic cancer centres, with administrative deviations predominating, followed by therapeutic and diagnostic deviations. This review advances current knowledge by consolidating contemporary evidence on VIP syndrome in oncology and highlighting institutional safeguards, standardized care pathways and ethics education as key strategies for promoting equitable, evidence based cancer care.

 

Keywords

Very important person (VIP) syndrome, oncology ethics, preferential care, healthcare equity, cancer care delivery

 

Citation

Mohan et al. Bioinformation 22(10): 6898-6902 (2026)

 

Edited by

Ritik Kashwani

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.